North Central Cancer Treatment Group (NCCTG) Biospecimen Resource

中北癌症治疗组 (NCCTG) 生物样本资源

• 批准号: 7990043
• 负责人: JAN C BUCKNER
• 金额: $ 87.28万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-17 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7990043
• 关键词: Body Fluids; Cancer Patient; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Collection; Commit; Communities; Community Clinical Oncology Program; Community Practice; Diagnosis; Diagnostic; Disease; Disease Progression; Education; Emerging Technologies; Enrollment; Information Systems; Laboratory Study; Leadership; Malignant Neoplasms; Marketing; Mission; North Central Cancer Treatment Group; Participant; Patients; Policies; Prevention approach; Procedures; Process; Qualifying; Quality of life; Research; Research Personnel; Resources; Retrieval; Role; Site; Specific qualifier value; Specimen; Systems Development; Testing; Translational Research; Treatment Protocols; Tumor Tissue; cancer care; cancer prevention; cancer therapy; community setting; improved; novel strategies; prognostic; response

DESCRIPTION (provided by applicant): The mission of the North Central Cancer Treatment Group (NCCTG) is to improve the duration and quality of life of cancer patients by performing high-quality clinical and translational research in the community setting. NCCTG was founded on the premise that cancer care in the U.S. occurs primarily in the community practice setting. Consequently, the community is the most appropriate venue for testing novel approaches to prevention, diagnosis, treatment, and symptomatic management of cancer. Since 2003, NCCTG has received more than 17,000 tumor tissue blocks from over 12,000 patients, and NCCTG has received over 38,000 body fluid biospecimens from more than 9,500 patients. Typically, specimens are received from 70 to 90% of patients from whom they are requested, and approximately 75% originate from community oncology sites. Consequently, specimens representative of the clinical trial participants are available in sufficient numbers to answer the scientific questions posed in the correlative laboratory studies. The NCCTG Biospecimen Resource will support the NCCTG mission by providing superior biospecimens from patients enrolled on NCCTG trials that 1) are fully and consistently annotated, 2) have been collected under optimized standard conditions, 3) have undergone quality assessment, and 4) are stored under controlled conditions allowing efficient retrieval for distribution to qualified researchers. The four specific aims of this application are: 1) to continue to optimize the collection and annotation of biospecimens obtained from patients enrolled on NCCTG and other cooperative group clinical trials; 2) to maintain standard operating procedures (SOPs) for collecting, processing and storing biospecimens; 3) to apply emerging technologies for collection and processing of biospecimens; and 4) to provide ongoing oversight to the resource and Improve marketing and education regarding access to the resource for the research community. NCCTG representatives will actively participate in Group Banking Committee (GBC) activities, will assume leadership roles within the GBC as appropriate, and will implement policies established by the GBC. NCCTG is committed to harmonization of GBC processes, including standard operating procedures, promotion of the resource, information systems, and development of new strategies during the proposed RELEVANCE: The NCCTG Biospecimen Resource provides large numbers of well-annotated biospecimens from patients enrolled in specified treatment protocols with definitive endpoints, thus, enabling research in markers diagnostic of a particular disease entity, prognostic of disease progression or predictive of response to treatment. Appropriate and efficient use of this resource is vital to promote the scientific mission of NCCTG, other cooperative groups, and the national research agenda for cancer prevention and treatment.

描述（由申请人提供）：中北癌症治疗小组 (NCCTG) 的使命是通过在社区环境中进行高质量的临床和转化研究来延长癌症患者的生活时间并提高其生活质量。 NCCTG 成立的前提是，美国的癌症护理主要发生在社区实践环境中。因此，社区是测试癌症预防、诊断、治疗和症状管理新方法的最合适场所。自2003年以来，NCCTG已收到来自12,000多名患者的17,000多个肿瘤组织块，NCCTG已收到来自9,500多名患者的38,000多个体液生物样本。通常情况下，70% 至 90% 的患者会收到标本，其中大约 75% 来自社区肿瘤中心。因此，有足够数量的代表临床试验参与者的样本来回答相关实验室研究中提出的科学问题。 NCCTG 生物样本资源将通过提供来自参加 NCCTG 试验的患者的优质生物样本来支持 NCCTG 的使命，这些生物样本 1) 具有完整且一致的注释，2) 在优化的标准条件下收集，3) 经过质量评估，4) 在受控条件下存储，允许有效检索并分发给合格的研究人员。该应用程序的四个具体目标是：1）继续优化从参加NCCTG和其他合作组临床试验的患者获得的生物样本的收集和注释； 2) 维持收集、处理和储存生物样本的标准操作程序（SOP）； 3）应用新兴技术采集和处理生物样本； 4) 对资源进行持续监督，并改进有关研究界资源获取的营销和教育。 NCCTG 代表将积极参与集团银行委员会 (GBC) 的活动，酌情在 GBC 内发挥领导作用，并执行 GBC 制定的政策。 NCCTG 致力于协调 GBC 流程，包括标准操作程序、资源推广、信息系统以及在提议期间制定新战略 相关性：NCCTG 生物样本资源提供了大量注释明确的生物样本，这些生物样本来自参加特定治疗方案的患者，具有明确的终点，从而能够对特定疾病实体的标记物诊断、疾病进展的预后或治疗反应的预测进行研究。适当、有效地利用这一资源对于促进 NCCTG、其他合作团体的科学使命以及癌症预防和治疗的国家研究议程至关重要。